HomeNDC LookupDrug shortages › Insulin Lispro-Aabc Injection

Insulin Lispro-Aabc Injection shortage

Insulin Lispro-Aabc Injection is currently listed in shortage by the FDA. The FDA lists 2 affected products. This page was last refreshed from FDA data on Sep 17, 2026.

To Be Discontinued ⚠ Supply risk: High Endocrinology/Metabolism 2 products 328 days First posted Oct 24, 2025 Updated Oct 24, 2025
Here’s the bottom line

Eli Lilly is permanently stopping the Lyumjev (insulin lispro-aabc) Tempo Pen. Lyumjev KwikPen, which contains the same medicine, is still listed by Eli Lilly as available in both U-100 and U-200 strengths.

Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).

Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →
2
Affected NDCs
1
Reporting manufacturers
0/1
Reporting mfrs supplying
0/2
Affected strengths / sizes supplied
328
Days in shortage
13
Medicaid Rx (2025)
Source: FDA Drug Shortages Database API (openFDA). Last refreshed Sep 17, 2026 · yesterday

What’s in shortage — at a glance

These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Insulin Lispro-Aabc Injection. Other makers that haven’t reported a problem are shown in the green card below.

Availability of affected NDCs
From the FDA shortage report
2 NDCs
To be discontinued 2
Affected strengths / sizes still supplied
Among manufacturers reporting this shortage
0/2 strengths / sizes
No supply 2
FDA-reporting manufacturers with supply
Among manufacturers reporting this shortage
0/1 makers
No supply 1
✓ Other manufacturers not reporting a shortage
Still-marketed Insulin Lispro-Aabc Injection from companies that have not filed an FDA shortage — these are not counted in the figures above. Stock can still vary by pharmacy.
Eli Lilly and Company
See all other options & details →
Shortage timeline
  1. Oct 24, 2025
    Currently in shortage
    2 of 2 products affected.
  2. Oct 24, 2025
    First reported to the FDA
    2 products first listed.

Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.

What exactly is on backorder — by manufacturer

Manufacturer: Eli Lilly and Co. 📞 800-545-5979 2 NDCS click to expand
Status NDC / product Strength / size Availability Related information Reason
To Be Discontinued Lyumjev, Injection, U-100 Tempo Pen Sample (NDC 0002-8235-99) NDC 00002-8235-99 A business decision was made to discontinue manufacture of the drug.
To Be Discontinued Lyumjev, Injection, U-100 Tempo Pen (NDC 0002-8235-05) NDC 00002-8235-05 A business decision was made to discontinue manufacture of the drug.

These rows are manufacturer reports to the FDA for Insulin Lispro-Aabc Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Insulin Lispro-Aabc Injection? options further down this page.

Why is Insulin Lispro-Aabc Injection in shortage?

Eli Lilly has made a business decision to permanently stop making Lyumjev (insulin lispro-aabc) in the U-100 Tempo Pen form — that includes both the regular U-100 Tempo Pen and the U-100 Tempo Pen Sample package. No specific reason beyond it being a business decision was shared publicly with the FDA.

It's worth knowing that this report covers only these two specific Tempo Pen presentations from Eli Lilly. The FDA did not provide a public explanation for why this business decision was made, so I can only share what was officially reported — that these particular packages are being permanently discontinued by the manufacturer.

Based on the manufacturer-reported reason(s) and notes on file with the FDA for Insulin Lispro-Aabc Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.

What should I do if I take Insulin Lispro-Aabc Injection?

Insulin Lispro-Aabc Injection (sold as Lyumjev) is currently on the FDA shortage list, and I want to walk you through what this means for you.

The two products affected are the U-100 Tempo Pen and the U-100 Tempo Pen Sample. Neither has an available source right now. There are no other strengths of the Tempo Pen still reported as available on this record.

The reason listed is a business decision by the manufacturer to discontinue making these products. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent, and there is no recovery date to share. That said, this affects the Tempo Pen form specifically — the same insulin is still made in other pen forms.

Here is what I suggest, in order:

  • Do not stop, skip, or change your doses on your own.
  • Ask your pharmacy to check whether they can still source your Tempo Pen through wholesalers.
  • The same medicine, Lyumjev, is still available in the Kwikpen (100 units/mL and 200 units/mL). Your pharmacy may be able to source one of these, though it may not be in local stock.
  • Since the Tempo Pen is being discontinued, talk with your prescriber or pharmacist about the right next step for you.

Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls.

This is general, national information and may not match your local pharmacy's actual stock.

See “Where else can I get Insulin Lispro-Aabc Injection?” below ↓ The same medicine from manufacturers not reporting a shortage, alternative dosage forms, and therapeutic equivalents with pricing.
If you are a patient:
  • Don’t stop or change the medication on your own — talk to your prescriber first.
  • If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
  • Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
  • Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Keep reading
Our full Insulin Lispro Injection guide

Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.

Read the Insulin Lispro Injection guide →

Where else can I get Insulin Lispro-Aabc Injection?

FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Insulin Lispro-Aabc Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.

Same medicine, other manufacturers (not reported short)

Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:

ProductStrengthForm / routeManufacturerNDC
Lyumjev Kwikpen INSULIN LISPRO 100 [iU]/mL Injection, Solution · Subcutaneous Eli Lilly and Company 00002-8207-05
Lyumjev Kwikpen INSULIN LISPRO 200 [iU]/mL Injection, Solution · Subcutaneous Eli Lilly and Company 00002-8228-27
Therapeutic equivalents & pricing 5 productsclick to expand

Orange Book–rated equivalents of the affected strengths / sizes, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.

ProductManufacturerPackageNADAC $/unitAB ratingAvailability
LYUMJEV Tempo Pen 100 [iU]/mLNDC 00002-8235-05 Eli 5 syringes $10.138 Availability likely
LYUMJEV KwikPen 100 [iU]/mLNDC 00002-8207-05 Eli 5 syringes $10.157 Availability likely
LYUMJEV Tempo Pen 100 [iU]/mLNDC 00002-8235-99 Eli 1 syringe FDA listed
Lyumjev 100 [iU]/mLNDC 00002-7726-05 Eli 5 cartridges FDA listed
LYUMJEV Junior KwikPen 100 [iU]/mLNDC 00002-8351-05 Eli 5 syringes FDA listed

Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.

Other drugs in the same treatment class

These are different medicines — not other versions of Insulin Lispro-Aabc Injection — that fall in the same broad treatment class (insulins) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.

Identity & classification

GCN Seq No 085478
GCN 54973
HICL code 046616
Ingredient (HICL) Insulin Lispro-Aabc
HIC1 code C
Therapeutic class — broad (HIC1) Electrolyte Balance/Metabolism/Nutrition
HIC2 code C4
Therapeutic class — intermediate (HIC2) Antihyperglycemics
HIC3 code C4G
Therapeutic class — specific (HIC3) Insulins
AHFS code 68:20.08.00
AHFS class Insulins
FDB label name LYUMJEV TEMPO PEN 100 UNIT/ML
FDB brand name Lyumjev Tempo Pen U-100
Legend status F — Federal legend — prescription drug or device
Where does this data come from?
Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.

Other endocrinology/metabolism shortages

Insulin Lispro-Aabc Injection shortage FAQs

Is Insulin Lispro-Aabc Injection in shortage?
Yes — the FDA currently lists Insulin Lispro-Aabc Injection in shortage (status: “To Be Discontinued”, first reported Oct 24, 2025). 2 of 2 products are affected. This is national, manufacturer-reported data, so your pharmacy may still have stock.
Which products are affected?
Lyumjev, Injection, U-100 Tempo Pen Sample (NDC 0002-8235-99) (NDC 00002-8235-99); Lyumjev, Injection, U-100 Tempo Pen (NDC 0002-8235-05) (NDC 00002-8235-05). The full per-NDC list (availability, manufacturer and status) is in the table above — each NDC links to its own page.
When will Insulin Lispro-Aabc Injection be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
Can I still get Insulin Lispro-Aabc somewhere?
Other manufacturers (Eli Lilly and Company) still market it and have not reported a shortage. See “Where else can I get Insulin Lispro-Aabc Injection?” above — stock still varies by pharmacy.
What should I do if I take Insulin Lispro-Aabc Injection?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another manufacturer or a different strength/package size, and ask your prescriber about a long-term plan before your supply runs out.

Still have a question about the Insulin Lispro-Aabc Injection shortage?

Ask a pharmacist about this shortage →
How to read the Supply-Risk rating
Low (1–2)Multiple manufacturers still supplying and most strengths or pack sizes sourceable.
Medium (3)Some constraint — fewer suppliers or a notable share of NDCs unavailable.
High (4–5)Down to a single source, most strengths or pack sizes unsourceable, or a long-running outage.
Where does this data come from?
Shortage records come from the FDA Drug Shortages Database API via openFDA (/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.
Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD.
← Back to all current drug shortages